The Celiac Disease Foundation congratulates David Baker, Demis Hassabis, and John Jumper on winning the 2024 Nobel Prize in Chemistry. Baker and his colleagues have transformed protein design, structure, and prediction using artificial intelligence, paving the way for the development of new therapeutics targeting specific proteins.
For the celiac community, these advancements are particularly significant. Baker’s work has directly contributed to the development of TAK-062, an investigational treatment aimed at improving gluten tolerance in individuals with celiac disease. The Celiac Disease Foundation is proud to support clinical trial recruitment for TAK-062 and other potential treatments, using our innovative iQualifyCeliac platform to connect patients with cutting-edge research. We remain committed to accelerating the development of new therapies and, ultimately, a cure for celiac disease.
“The work of David Baker, Demis Hassabis, and John Jumper has the potential to redefine what’s possible in therapeutic development,” said Marilyn Geller, CEO of the Celiac Disease Foundation. “Their advancements in protein design open new possibilities for treatments that could significantly improve outcomes for people with celiac disease. We are eager to see how their research will continue to shape the future of medicine.”
Learn more about our efforts and current clinical trials at celiac.org/trials.